BNCT

TAE Life Sciences' Neutron Beam System Receives Acceptance, Allowing BNCT Clinical Trials to Begin in China

Retrieved on: 
Wednesday, April 3, 2024
Neutron, NBS, Growth, Patient, Cancer, Key, BNCT, Pharmaceutical industry

IRVINE, Calif., April 3, 2024 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator-based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption. Developed and manufactured in the United States, TAE Life Sciences' NBS has met all specifications outlined by Neuboron Medical and the local regulatory body, enabling human BNCT clinical trials to begin this month in China.

Key Points: 
  • Developed and manufactured in the United States, TAE Life Sciences' NBS has met all specifications outlined by Neuboron Medical and the local regulatory body, enabling human BNCT clinical trials to begin this month in China.
  • The completion of acceptance testing underscores TAE Life Sciences' commitment to international safety and efficacy standards, making it the first US company to have its system achieve such recognition.
  • This major technological progress demonstrates how TAE Life Sciences has solidified its leading position in the growing field of BNCT.
  • For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com .

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

Retrieved on: 
Tuesday, March 12, 2024
Neutron, Radiation, Patent, Tyrosine, Research, BTS, Cancer, Ome, BNCT, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company's U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.

Key Points: 
  • US 11,884,688 B2 , for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT).
  • This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.
  • "This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams.
  • With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

TAE Life Sciences to Present Groundbreaking Developments in Cancer Drug Development at Biotech Showcase 2024

Retrieved on: 
Wednesday, December 27, 2023
Neutron, JPM, Conference, Medicine, ABC, CH2, Biotechnology, Antibody, FC, TAE, SAN, Cancer, BNCT, Hill, Radiation, Patient, BTS, Therapy, ADC, Vaccine

SAN FRANCISCO, Dec. 27, 2023 /PRNewswire/ -- At the forefront of pioneering advancements in the field of radiation oncology, TAE Life Sciences is set to unveil significant strides in its innovative drug development at the esteemed Biotech Showcase, taking place in parallel to the 42nd annual J.P. Morgan Healthcare Conference (JPM).

Key Points: 
  • At the event, Rob Hill, Chief Executive Officer of TAE Life Sciences, will unveil groundbreaking insights derived from recent studies on BTS, the company's proprietary boronated drug designed for Boron Neutron Capture Therapy (BNCT).
  • This development holds significant promise for BNCT—a highly precise and targeted radiation therapy applicable to various cancer types.
  • Details about Rob Hill's presentation at Biotech Showcase 2024:
    TAE Life Sciences invites interested stakeholders and investors to attend Rob's presentation to gain deeper insights into these transformative developments and explore potential collaborations.
  • For more information about TAE Life Sciences, BTS, engineered antibody drugs, and Alphabeam BNCT system, please visit www.taelifesciences.com .

Neutron Therapeutics' Accelerator Receives Final Acceptance at University of Birmingham's High Flux Accelerator-Driven Neutron Facility

Retrieved on: 
Wednesday, December 13, 2023
Science, Biotechnology, Research, Health, Energy, University, Education, Nuclear, Neutron, Outline of physical science, High Flux Isotope Reactor, Therapy, Physics, Head, Glioblastoma, BNCT, Teaching hospital, Radiation, Medicine, Nuclear energy, United, BEI, University of Birmingham, Engineering, Cancer, EPSRC, Environment, Lithium, Medical imaging

Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham's High Flux Accelerator-Driven Neutron Facility.

Key Points: 
  • Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham's High Flux Accelerator-Driven Neutron Facility.
  • This first-of-its-kind facility will enable research into the effects of neutrons in a variety of fields, including nuclear energy, nuclear science and boron neutron capture therapy (BNCT).
  • This facility is the United Kingdom’s first high-flux neutron test facility.
  • “The compact accelerator at the University of Birmingham’s neutron facility provides an excellent environment for researchers conducting pre-clinical research in boron neutron capture therapy,” said Professor Stuart Green, director of medical physics at University Hospital Birmingham.

TAE Life Sciences Earns Oncology Innovation of the Year Award

Retrieved on: 
Wednesday, November 8, 2023
Neutron, TAE, Radiation, Biotechnology, Head, BPA, BNCT, Lithium, Neutron capture therapy of cancer, Cancer, Hospital, Boron, Collateral damage, DNA, Pharmaceutical industry, Medical imaging

IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year. This prestigious accolade acknowledges TAE Life Sciences' pioneering work in radiation oncology and highlights the role its innovative Alphabeam™ Neutron System and proprietary boronated drugs are playing in making Boron Neutron Capture Therapy (BNCT) a mainstay of modern oncology.

Key Points: 
  • IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- TAE Life Sciences , a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
  • This versatility, coupled with its potential to treat various types of cancers, grants TAE our 'Oncology Innovation of the Year' award."
  • TAE Life Sciences is committed to advancing the frontiers of oncology through innovation and patient-focused care.
  • For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com .

Aviko Radiopharmaceuticals and Neutron Therapeutics Form Exclusive, Strategic Partnership with Leo Cancer Care to Expand Development of Boron Neutron Capture Therapy for Treating Cancer

Retrieved on: 
Monday, October 2, 2023
Oncology, Health, Medical Devices, General Health, Radiology, Pharmaceutical, Biotechnology, Neutron, Partnership, ASTRO, Radiopharmaceutical, Cancer, Multimedia, Void coefficient, Radiation therapy, Patient, Physician, BNCT, Annual general meeting, Neoplasm, FDA, Therapy, Society, Pharmaceutical industry, Medical imaging

Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care , a company developing upright patient positioning systems for radiation therapy.

Key Points: 
  • Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care , a company developing upright patient positioning systems for radiation therapy.
  • The goal of the partnership between the three companies is to expand BNCT as a potential treatment for different types of cancer.
  • Positioning the patient in relation to the neutron beam is important to support patient safety and the clinical activity of BNCT.
  • We are excited to collaborate with Aviko and Neutron as we advance BNCT to potentially treat a variety of solid tumors.”
    The products being developed by Aviko Radiopharmaceuticals, Neutron Therapeutics and Leo Cancer Care are in development and are limited to investigational use.

TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting

Retrieved on: 
Thursday, September 28, 2023
Neutron, BTS, Augmented reality, ASTRO, Cancer, Hope, RaySearch Laboratories, Research, Radiation therapy, Neutron capture therapy of cancer, MD, Patient, BNCT, SAN, BPA, ABC, American Society for Radiation Oncology, Spacecraft, Society, AR, Technical, Pharmaceutical industry, Fine chemical

"We're on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system.

Key Points: 
  • "We're on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system.
  • TAE Life Sciences will host a presentation, titled "Reimagining BNCT for Biologically Targeted Radiation Therapy," at its booth stage on October 1 at 11:00 AM.
  • At ASTRO, TAE Life Sciences will have several exciting exhibits on display in its booth, including:
    BNCT treatment planning demonstration featuring TAE Life Sciences' proprietary dose engine running on the Raysearch treatment planning engine.
  • For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com .

Rob Hill Promoted to TAE Life Sciences CEO as Company Prepares Pursuit of Clinical Trials Globally

Retrieved on: 
Tuesday, July 25, 2023
Neutron, Rich Man (TV series), Accuray, TAE, Clinical trial, Boron, Cancer, Radiation, Patient, BNCT, TAE Technologies, Growth, Hill, Management, Pharmaceutical industry, Medical imaging

IRVINE, Calif., July 25, 2023 /PRNewswire/ -- The board of directors of TAE Life Sciences, a pre-clinical stage biotech company focused on advancing the field of radiation oncology through accelerator-based Boron Neutron Capture Therapy (BNCT), is pleased to announce the appointment of Rob Hill as its new Chief Executive Officer (CEO). Effective immediately, Hill succeeds Bruce Bauer who has served as CEO since the company was founded in 2017. Bauer, stepping aside for medical reasons, will remain active on the board of directors as chairman emeritus.

Key Points: 
  • Effective immediately, Hill succeeds Bruce Bauer who has served as CEO since the company was founded in 2017.
  • "I am truly honored to lead TAE Life Sciences, a company poised to revolutionize cancer treatment and save countless lives," said Hill.
  • Before joining TAE Life Sciences, Hill held various senior executive positions at Accuray Incorporated, a renowned provider of radiation oncology solutions.
  • Click here to view TAE Life Sciences' latest video where Rob Hill presents his vision of how TAE Life Sciences is reinventing radiation therapy for cancer patients.

TAE Life Sciences Takes Center Stage at PTCOG: Co-Hosting BNCT Symposium and Unveiling Groundbreaking Small Molecule Drug Development for BNCT

Retrieved on: 
Friday, June 9, 2023
Neutron, Molecule, Drink, GBM, Spallation Neutron Source, Neoplasm, Food, Boron, Drug, Morrison, Present, Head, Breast, Research, Neck, Solubility, Lung, Glioblastoma, Future, Organization, Neutron capture therapy of cancer, Particle, BNCT, Melanoma, BPA, Cancer, News, Pharmaceutical industry

MADRID and IRVINE, Calif., June 9, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneering company in the field of cancer treatment, announces its participation in the 61st annual Particle Therapy Co-Operative Group (PTCOG) conference in Madrid, Spain. The event, held from June 10 – 16, 2023, will bring together leading experts, researchers, and organizations dedicated to advancing particle therapy in cancer treatment. TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).

Key Points: 
  • TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).
  • Morrison will discuss the breakthrough work conducted by TAE Life Sciences in developing targeted boronated small molecule drugs as alternatives to 4-boronophenylalanine (BPA).
  • TAE Life Sciences will also have a poster presentation at PTCOG showcasing the technical details of its tandem-architecture neutron beam system for BNCT cancer treatment.
  • TAE Life Sciences invites conference attendees and media representatives to attend Tuesday evening's symposium to learn more about the latest BNCT device and drug innovations and breakthroughs.

Aviko Radiopharmaceuticals and Neutron Therapeutics Form Strategic Partnership to Advance Boron Neutron Capture Therapy

Retrieved on: 
Thursday, June 8, 2023
Biotechnology, Health, Pharmaceutical, Health Technology, Oncology, Neutron, Acceleration, Partnership, Drug development, AUC, Neoplasm, Helsinki University Central Hospital, Radiopharmaceutical, Cancer, Multimedia, Patient, BNCT, Medicine, Therapy, Pharmaceutical industry

Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , the leading provider of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced the formation of a strategic partnership to advance BNCT to treat cancer.

Key Points: 
  • Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , the leading provider of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced the formation of a strategic partnership to advance BNCT to treat cancer.
  • The partnership aligns the companies’ efforts to build the first BNCT treatment center in the United States and to establish additional BNCT facilities through collaborations with premier academic medical centers.
  • Aviko has developed a pipeline of boron medicines that exhibit properties to enable effective BNCT, including high tumor selectivity.
  • “This partnership is an example of how two companies can collaborate to advance a promising therapy to help patients who are in need of more effective treatment options.”
    Ted Smick, chief technology officer and co-founder of Neutron Therapeutics, added: “Together, Aviko and Neutron Therapeutics offer a complete solution for BNCT, enabling more medical centers to provide this powerful new treatment to patients.”